ketoconazole has been researched along with Dyspnea in 1 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Dyspnea: Difficult or labored breathing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty patients with COPD (10 women and 10 men; age, 70 ± 8 years) inspired through resistances during practice sessions to identify an individualized target load that caused ratings of intensity and unpleasantness of breathlessness ≥ 50 mm on a 100-mm visual analog scale." | 2.78 | Effect of increased blood levels of β-endorphin on perception of breathlessness. ( Gifford, AH; Harver, A; Kraemer, WJ; Kupchak, BR; Mahler, DA; Ward, J; Waterman, LA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahler, DA | 1 |
| Gifford, AH | 1 |
| Waterman, LA | 1 |
| Ward, J | 1 |
| Kraemer, WJ | 1 |
| Kupchak, BR | 1 |
| Harver, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ketoconazole on Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease[NCT01378520] | Phase 4 | 20 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change between pre-treatment and post treatment serum levels of beta-endorphin immunoreactivity measured in pmol/L (NCT01378520)
Timeframe: At the end of resistance load breathing (4.5 hours after receiving the test article)
| Intervention | pmol/L (Mean) |
|---|---|
| Ketoconazole | 153.9 |
| Inert Powder | 93.9 |
"The average of all ratings for the intensity of breathlessness at equivalent times for each subject during Resistive Load Breathing (RLB). For example, if 1 subject provided 6 ratings during 6 minutes of RLB with Ketoconazole and 10 ratings during 10 minutes of RLB with inert powder, then ratings for intensity through 6 minutes were used for analysis for that patient. This approach was used for all subjects to yield a total of 252 ratings for Ketoconazole and for inert powder.~Subject rating of intensity of breathlessness was obtained at 1 minute intervals during RLB on a 100 mm Visual Analog Scale anchored at the bottom by No Intensity and at the top by Greatest Intensity." (NCT01378520)
Timeframe: At 1 minute intervals during Resistive Load Breathing at Period 1 (Day 3 or 4) and Period 2 (Day 5, 6 or 7)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketoconazole | 77.6 |
| Inert Powder | 78.2 |
"The average of all ratings for the unpleasantness of breathlessness at equivalent times for each subject during Resistive Load Breathing (RLB). For example, if 1 subject provided 6 ratings during 6 minutes of RLB with Ketoconazole and 10 ratings during 10 minutes of RLB with inert powder, then ratings for unpleasantness through 6 minutes were used for analysis for that patient. This approach was used for all subjects to yield a total of 252 ratings for Ketoconazole and for inert powder.~Subject rating of intensity of unpleasantness was obtained during RLB on a 100 mm Visual Analog Scale anchored at the bottom by No Unpleasantness and at the top by Greatest Unpleasantness." (NCT01378520)
Timeframe: At 1 minute intervals during Resistive Load Breathing at Period 1 (Day 3 or 4) and Period 2 (Day 5, 6 or 7)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketoconazole | 72.5 |
| Inert Powder | 72.6 |
1 trial available for ketoconazole and Dyspnea
| Article | Year |
|---|---|
Effect of increased blood levels of β-endorphin on perception of breathlessness.
Topics: Adrenocorticotropic Hormone; Aged; beta-Endorphin; Biomarkers; Dyspnea; Female; Humans; Ketoconazole | 2013 |